source
- FDA lifts opposition to Huntington’s disease gene therapy, clearing path for developmentThe Readout Loud podcast this week highlighted a regulatory shift for a gene therapy aimed at Huntington’s disease. The Food and Drug Administration reversed its earlier opposition, removing a key…
- Biogen to acquire RayThera in up to $1 billion deal for immunology pipelineBiogen announced it will acquire RayThera, a startup founded in 2023, in a deal valued at up to $1 billion. The acquisition gives Biogen access to RayThera’s immunology pipeline, which includes th…